Market Capitalization (Millions $) |
1 |
Shares
Outstanding (Millions) |
16 |
Employees |
- |
Revenues (TTM) (Millions $) |
20 |
Net Income (TTM) (Millions $) |
-24 |
Cash Flow (TTM) (Millions $) |
-22 |
Capital Exp. (TTM) (Millions $) |
1 |
Sunshine Biopharma Inc
Sunshine Biopharma Inc is a pharmaceutical research and development company based in Canada. The company focuses on developing treatments for various forms of cancer, including pancreatic cancer and breast cancer. Their flagship product is Adva-27a, a chemotherapy drug being developed for pancreatic cancer treatment.
Sunshine Biopharma Inc utilizes a unique approach to drug development by leveraging their proprietary research platform, which combines computer modeling with traditional laboratory techniques. This approach allows them to identify and target specific molecular targets that are crucial for cancer cell survival.
The company's goal is to develop innovative and more effective treatments for cancer patients, with a focus on improving patient outcomes and quality of life. They aim to bring their drug candidates through the necessary stages of preclinical and clinical trials in order to obtain regulatory approval and make them available to patients in need.
Overall, Sunshine Biopharma Inc is dedicated to advancing the field of cancer research and providing hope to patients by developing novel therapies that could potentially make a significant impact in the fight against cancer.
Company Address: 6500 Trans-Canada Highway Quebec 0
Company Phone Number: 426-6161 Stock Exchange / Ticker: NASDAQ SBFM
SBFM is expected to report next financial results on April 02, 2024. |
|
|